Unlocking Potential: Personalized Lifestyle Therapy for Type 2 Diabetes Through a Predictive Algorithm-Driven Digital Therapeutic
Authors' conclusion
These results indicate that the DTx has clinically relevant effects on glycemic control and weight reduction for patients with both well and poorly controlled diabetes, whether through single or repeated usage. It is a noteworthy improvement in T2D management, offering a non-pharmacological, fully digital solution that integrates biofeedback through CGM and an advanced AI algorithm.
Study context
- Population
- Adults with non-insulin-treated T2D (HbA1c ≥ 6.5%) already receiving standard care; mean baseline HbA1c 7.46% (0.93)
- Participants
- 118 adults
- Comparison
- DTx for 3 months, pre-post
- DTxn = 118
- Outcome
- HbA1c change from baseline
- Follow-up
- Three months
Methodological detailssingle-group, pre-post comparison
- Single-group
- Pre-post comparison
Main finding
As reported in the abstract
HbA1c improvement, complete cohort
0.67%
HbA1c change, poorly controlled diabetes (BL-HbA1c ≥ 7.0%), vs standard of care (P < .001)
−1.08%
Further findings
Patients within therapeutic target range (HbA1c < 7.0%) · three months
- Increased from baseline
- 38% to 60%
- On the way to remission (< 6.5%)
- 33%
Second use of DTx: HbA1c and weight vs baseline · six months
- HbA1c reduction
- −0.76%
- Mean weight loss (P < .001)
- −6.84 kg
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →